All News

psA.fil_.Hands_.jpg

What’s New in Psoriatic Arthritis: A Whirlwind Tour

Jiha Lee, MD

At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.

Read Article
several white balls with one red ball in the middle

CAR-T Reaches the Synovium: COMPARE Phase 1 in ACPA-Positive RA

Henrique Dalmolin, MD

Treatment-refractory RA is more common than we sometimes admit. Roughly 11% of patients fail multiple b/tsDMARD classes, and for the ACPA-positive subset, rituximab has long been the fallback. It works, but it rarely produces durable disease-free intervals. CD19 CAR T-cell therapy was always going to be the question that followed the SLE data. Until EULAR 2026, that question had no prospective answer. The plenary session changed that.

Read Article
light bulb idea

Three Abstracts That May Shape the Future of RA Treatment

Aurelie Najm, MD, PhD

Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice? Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.

Read Article
change,future,lens,clarity

‘Strong’ treatment predictions in inflammatory myositis

Janet Pope, MD, MPH, FRCPC

Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).

Read Article
#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Have you ever thought of diclofenac as an environmental pollutant? Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026 @rheumnow https://t.co/RJWB6DmiZh

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP. At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+ POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr

Links:

sheila RHEUMarampa ( View Tweet)

#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up. Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Live vaccinations in infants antenatally exposed to bDMARDs ⬇️⬇️ #WIN session @lauraandreoli80 #EULAR2026 @RheumNow https://t.co/84MCwb2fbT

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ivarmacitinib (selective JAK1 inhibitor) significantly improved ASAS40 vs placebo in nr-#axSpA(39.7% vs 24.8%; p=0.006) at 12 weeks, sustained to 24 weeks. Another oral option for non-radiographic disease. Abstr OP0237 @RheumNow #EULAR2026

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

DR JOHN STONE gives Overview Of #IgG4 New non B cell depleter #obexelimab N=194 in RCT To add to B cell depletion w #Inebilizumab Off label but used also #Rituximab #steroids #Immunesuppressives Other investigational drugs Ex #JAKi #EULAR2026 @RheumNow #OP018 #RULARbest https://t.co/Y4saGYcdww

Links:

Janet Pope Janetbirdope ( View Tweet)
💉 Does bimekizumab work in real-world PsA? YES - EuroSpA: 76% retention at 6months 46% DAPSA LDA in 787pts across 12 registries #OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach), Non peptide based (can be given anytime). Know about s/e and contraindications. May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar. #EULAR2026 @RheumNow https://t.co/KNudYN29PT

Links:

Bella Mehta bella_mehta ( View Tweet)
Prof. Wittmann discusses the current tx for CLE using a stepwise approach. Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ

Links:

sheila RHEUMarampa ( View Tweet)
#EULAR2026 OP022 We need to think beyond proteinuria to assess activity & response in #lupusnephritis. ReBioLup study showed 67% of patients with persistent histologic activity at 12 months (NIH=>4) still met criteria for complete clinical response @RheumNow https://t.co/bRFNrNLjJX

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×